Program
trastuzumab deruxtecan
Also written as “Trastuzumab deruxtecan”, “Trastuzumab Deruxtecan” and “DS-8201a”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyo | 2611 open or running | phase 3since Apr 13, 2018 | Sep 21, 2015 | Oct 1, 2027phase 3 · NCT05950945 |
| AstraZeneca | 2120 open or running | phase 4since May 21, 2024 | Sep 22, 2017 | Feb 10, 2027phase 2 · NCT06271837 |
| Pfizer | 10 open or running | phase 2since Aug 31, 2020 | Aug 31, 2020 | none ahead |
| Strata Oncology | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: Parexel, Merck, Bristol-Myers Squibb and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 37 studies since Sep 21, 2015.
- Jan 19, 2024Phase 2 study in Breast NeoplasmsAstraZeneca · NCT06271837 · 127 enrolled · China
- May 21, 2024Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT06467357 · 620 planned · United States, Australia, Austria and more
- May 21, 2024Phase 4 study in Breast NeoplasmsAstraZeneca · NCT06429761 · 100 enrolled · India
- Dec 9, 2024Phase 3 study in Stomach NeoplasmsDaiichi Sankyo · NCT06731478 · 726 planned · United States, Argentina, Australia and more
- Dec 12, 2024Phase 3 study in HER2-positive Gastric CancerAstraZeneca · NCT06764875 · 840 planned · United States, Argentina, Australia and more
- Feb 5, 2025Phase 3 study in Ovarian NeoplasmsDaiichi Sankyo · NCT06819007 · 582 planned · United States, Australia, Austria and more
- Mar 11, 2025Phase 3 study in Endometrial NeoplasmsAstraZeneca · NCT06989112 · 600 planned · United States, Australia, Austria and more
- Mar 21, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungDaiichi Sankyo · NCT06899126 · 686 planned · United States, Argentina, Belgium and more
- Jun 3, 2025Phase 1 study in RecurrenceDaiichi Sankyo · NCT07015697 · 76 planned · United States, Brazil, France and more
- Jun 6, 2025Phase 3 study in Endometrial NeoplasmsDaiichi Sankyo · NCT07022483 · 710 planned · United States, Argentina, Chile and more
- Jun 24, 2025Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712 · 100 planned · United States, Canada, China and more
- Jun 25, 2026Phase 3 study in Breast NeoplasmsDaiichi Sankyo · NCT07683754 · 200 planned · United States
- Oct 22, 2026Primary completion moved from 2026-11-11 to 2027-05-03Date moved laterphase 3 · +6 months · NCT04784715
- Oct 26, 2026Primary completion moved from 2026-08-03 to 2028-02-17Date moved laterphase 3 · +18 months · NCT06174987
Ahead
- Feb 10, 2027Primary completion: phase 2 study in Breast NeoplasmsAstraZeneca · NCT06271837
- Mar 23, 2027Primary completion: phase 2 study in Pancreatic NeoplasmsAstraZeneca · NCT04482309
- May 3, 2027Primary completion: phase 3 study in Breast NeoplasmsAstraZeneca · NCT04784715
- May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT04379596
TargetBeta
“An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 binding agent”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 49 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07683754Breast Neoplasms · United States | 3 | Recruiting | Daiichi Sankyo | Jul 4, 2030 | 200 |
| NCT07069712Stomach Neoplasms · United States, Canada, China and more | 2 | Recruiting | AstraZeneca | Nov 9, 2027 | 100 |
| NCT07022483Endometrial Neoplasms · United States, Argentina, Chile and more | 3 | Recruiting | Daiichi Sankyo | Feb 26, 2030 | 710 |
| NCT07015697Recurrence · United States, Brazil, France and more | 1 | Recruiting | Daiichi Sankyo | Dec 31, 2028 | 76 |
| NCT06899126Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Recruiting | Daiichi Sankyo | Apr 24, 2030 | 686 |
| NCT06989112Endometrial Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Jan 19, 2029 | 600 |
| NCT06819007Ovarian Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Daiichi Sankyo | Nov 1, 2028 | 582 |
| NCT06764875HER2-positive Gastric Cancer · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Apr 27, 2029 | 840 |
| NCT06731478Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Daiichi Sankyo | Jun 1, 2028 | 726 |
| NCT06467357Biliary Tract Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Jun 12, 2028 | 620 |
| NCT06429761Breast Neoplasms · India | 4 | Active, not recruiting | AstraZeneca | Oct 31, 2026 | 100 |
| NCT06271837Breast Neoplasms · China | 2 | Active, not recruiting | AstraZeneca | Feb 10, 2027 | 127 |
| NCT06174987Neoplasm Metastasis · United States, Australia, Brazil and more | 3 | Recruiting | Daiichi Sankyo | Feb 17, 2028 | 75 |
| NCT05950945Breast Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Daiichi Sankyo | Oct 1, 2027 | 250 |
| NCT05246514HER2-mutant Non-Small Cell Lung Cancer · China | 2 | Active, not recruiting | AstraZeneca | Nov 4, 2024 | 72 |
| NCT05113251Breast Neoplasms · United States, Brazil, Bulgaria and more | 3 | Active, not recruiting | AstraZeneca | Mar 12, 2025 | 927 |
| NCT05097599Neoplasms · United States | 2 | Terminated | Strata Oncology | Jun 12, 2024 | 11 |
| NCT05048797Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jun 9, 2026 | 454 |
| NCT04989816Adenocarcinoma · China | 2 | Completed | AstraZeneca | Jun 16, 2023 | 95 |
| NCT04784715Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | AstraZeneca | May 3, 2027 | 1,157 |
| NCT04739761Breast Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Feb 8, 2024 | 506 |
| NCT04744831Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Daiichi Sankyo | Nov 1, 2022 | 122 |
| NCT04704934Stomach Neoplasms · Argentina, Belgium, Brazil and more | 3 | Active, not recruiting | Daiichi Sankyo | Aug 31, 2026 | 490 |
| NCT04686305Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 1 | Recruiting | AstraZeneca | Jun 30, 2027 | 304 |
| NCT04644237Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Completed | Daiichi Sankyo | Dec 23, 2022 | 152 |
| NCT04622319HER2-Positive Primary Breast Cancer · United States, Argentina, Australia and more | 3 | Active, not recruiting | Daiichi Sankyo | Jul 2, 2025 | 1,600 |
| NCT04639219Neoplasm Metastasis · United States, Belgium, Canada and more | 2 | Active, not recruiting | AstraZeneca | Jan 25, 2023 | 102 |
| NCT04556773Breast Neoplasms · United States, Australia, Belgium and more | 1 | Active, not recruiting | AstraZeneca | Aug 16, 2023 | 138 |
| NCT04539938Breast Neoplasms · United States | 2 | Completed | Pfizer | Jul 15, 2024 | 70 |
| NCT04538742Breast Neoplasms · United States, Australia, Brazil and more | 2 | Active, not recruiting | AstraZeneca | Jan 31, 2025 | 245 |
| NCT04494425Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Mar 18, 2024 | 866 |
| NCT04482309Pancreatic Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | AstraZeneca | Mar 23, 2027 | 477 |
| NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more | 2 | Active, not recruiting | AstraZeneca | May 4, 2027 | 452 |
| NCT04042701Breast Neoplasms · United States, France, Spain and more | 1 | Active, not recruiting | Daiichi Sankyo | Jul 21, 2025 | 115 |
| NCT04014075Neoplasm Metastasis · United States, Belgium, Italy and more | 2 | Completed | Daiichi Sankyo | Nov 8, 2021 | 79 |
| NCT03734029Breast Neoplasms · United States, Austria, Belgium and more | 3 | Completed | Daiichi Sankyo | Jan 11, 2022 | 557 |
| NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more | 2 | Active, not recruiting | AstraZeneca | Nov 29, 2024 | 243 |
| NCT03523572Breast Neoplasms · United States, Belgium, France and more | 1 | Completed | Daiichi Sankyo | Jul 22, 2021 | 86 |
| NCT03529110Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Daiichi Sankyo | May 21, 2021 | 524 |
| NCT03523585Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Daiichi Sankyo | Jun 30, 2022 | 608 |
| NCT03505710Carcinoma, Non-Small-Cell Lung · United States, France, Japan and more | 2 | Terminated | Daiichi Sankyo | May 3, 2021 | 181 |
| NCT03384940Colorectal Neoplasms · United States, Italy, Japan and more | 2 | Completed | Daiichi Sankyo | Aug 9, 2019 | 86 |
| NCT03383692Neoplasm Metastasis · Japan, Korea, Republic of, Taiwan | 1 | Completed | Daiichi Sankyo | Sep 26, 2018 | 40 |
| NCT03368196Adenocarcinoma · Taiwan | 1 | Completed | Daiichi Sankyo | Sep 14, 2018 | 12 |
| NCT03366428Breast Neoplasms · Japan | 1 | Completed | Daiichi Sankyo | Dec 5, 2018 | 51 |
| NCT03329690Gastrointestinal Neoplasms · Japan, Korea, Republic of | 2 | Completed | Daiichi Sankyo | Nov 8, 2019 | 233 |
| NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | AstraZeneca | Sep 13, 2024 | 528 |
| NCT03248492Breast Neoplasms · United States, Belgium, Canada and more | 2 | Terminated | Daiichi Sankyo | Mar 21, 2019 | 253 |
| NCT02564900Neoplasms · United States, Japan | 1 | Completed | Daiichi Sankyo | Feb 1, 2019 | 292 |
How it is read
Names in the registry
- “Trastuzumab deruxtecan”, 22 entries
- “Trastuzumab Deruxtecan”, 10 entries
- “DS-8201a”, 7 entries
- “Trastuzumab deruxtecan (DS-8201a)”, 3 entries
- “T-DXd”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 19 studies
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Stomach Neoplasms, 5 studies
- Neoplasm Metastasis, 4 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.